BioSpace News Archive

According to the current analysis of Reports and Data, the global Healthcare Predictive Analytics market was valued at USD 3.74 Billion in 2019 and is expected to reach USD 28.77 Billion by the year 2027, at a CAGR of 28.9 %.

According to the current analysis of Reports and Data, the global Hemoglobinopathies market was valued at USD 5.84 Billionin 2019 and is expected to reach USD 15.05 Billion by year 2027, at a CAGR of 10.2% from 2020-2027.

AIDS Healthcare Foundation (AHF) today is calling for monkeypox to be treated as, and formally classified as a sexually transmitted infection (STI).

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), today announced that a Marketing Authorization Application (MAA) for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D) has been submitted to and successfully validated by the European Medicines Agency (EMA).

via NewMediaWire – Sono-Tek Corporation, the leading developer and manufacturer of ultrasonic coating systems, announced that it held its Annual Shareholders Meeting on August 18, 2022 at the Company’s headquarters in Milton, New York.

Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), will announce its second quarter 2022 financial results after market close on Thursday, August 25, 2022.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that the US Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for B-VEC for the treatment of patients with dystrophic epidermolysis bullosa (DEB).

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular transfusions were published on August 18, 2022, in The Lancet Haematology.